/wp-content/uploads/2025/03/logo-color.png00simon/wp-content/uploads/2025/03/logo-color.pngsimon2025-03-21 11:04:102025-09-15 16:37:29Soluble microneedle patch was granted a Taiwan Utility Model Patent
/wp-content/uploads/2025/03/logo-color.png00simon/wp-content/uploads/2025/03/logo-color.pngsimon2025-03-01 11:15:142025-09-12 11:15:31“COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS OR FACILITATING HAIR GROWTH” Granted a Taiwan Patent
/wp-content/uploads/2025/03/logo-color.png00simon/wp-content/uploads/2025/03/logo-color.pngsimon2025-01-15 16:34:342025-09-15 16:34:56Soluble microneedle patch has completed a cosmetic clinical study in Korea
https://blueblood.com.tw/wp-content/uploads/2024/09/dna-genetic-biotechnology-science-with-scientist-rsquo-s-hands-disruptive-technology-remix.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302024-06-01 12:00:472025-07-01 10:21:20Completed mass production of dissolvable microneedle products.
https://blueblood.com.tw/wp-content/uploads/2024/09/3d-render-medical-background-with-dna-strands-connecting-dots-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302024-01-01 12:00:282025-06-24 17:38:42BB-101 Phase II clinical trial approved by the Ministry of Economic Affairs, receiving a subsidy of NT$34 million under the ‘A+ Enterprise Innovation R&D Program – Fast-Track Clinical Trial Review.’
https://blueblood.com.tw/wp-content/uploads/2025/03/carbon-nanotubes-nanotechnology-3d-rendering-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302023-06-01 12:00:162025-06-24 17:38:56BB-101 drug received Taiwan FDA approval for clinical trials and began Phase II clinical trials at 3 medical centers in Taiwan.
https://blueblood.com.tw/wp-content/uploads/2025/03/carbon-nanotubes-nanotechnology-3d-rendering-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302023-03-01 12:00:262025-06-24 17:39:05Submitted application to Taiwan FDA to conduct BB-101 Phase II clinical trial.
https://blueblood.com.tw/wp-content/uploads/2025/03/carbon-nanotubes-nanotechnology-3d-rendering-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302023-01-01 12:00:552025-06-24 17:38:24Submitted application to the US FDA to conduct BB-101 Phase II clinical trial.
https://blueblood.com.tw/wp-content/uploads/2024/09/3d-render-medical-background-with-dna-strands-connecting-dots-拷貝.jpg8001200agent30/wp-content/uploads/2025/03/logo-color.pngagent302022-12-01 12:00:212025-06-27 09:38:41Launched GMP-certified high-performance pet skin renewal spray, entering the pet healthcare market.
Soluble microneedle patch was granted a Taiwan Utility Model Patent
“COMPOSITIONS AND METHODS FOR TREATING HAIR LOSS OR FACILITATING HAIR GROWTH” Granted a Taiwan Patent
Soluble microneedle patch has completed a cosmetic clinical study in Korea
Completed mass production of dissolvable microneedle products.
Licensed androgenic alopecia technology to Sanar Biotech Corp. through patent valuation.
BB-101 Phase II clinical trial approved by the Ministry of Economic Affairs, receiving a subsidy of NT$34 million under the ‘A+ Enterprise Innovation R&D Program – Fast-Track Clinical Trial Review.’
BB-101 drug received Taiwan FDA approval for clinical trials and began Phase II clinical trials at 3 medical centers in Taiwan.
Submitted application to Taiwan FDA to conduct BB-101 Phase II clinical trial.
Submitted application to the US FDA to conduct BB-101 Phase II clinical trial.
Launched GMP-certified high-performance pet skin renewal spray, entering the pet healthcare market.